Wall Street can be cruel that way.
Surfaxin is a humanized surfactant so, therefore, better than existing competitors, which are all animal-based. That should help Surfaxin gain market share but the total U.S. market is only $75 million, probably a bit more in Europe. It's a niche drug in a niche indication, which also helps explain why Discovery's stock price hasn't taken off following approval.
-- Written by Adam Feuerstein in Boston
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts